Digestive Disease Week

The treatment recently became the first ever FDA-approved medication for EoE.

Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.

Initial studies have shown a 73% efficacy for FMT in treating patients with HVGD.

BMI did not have an association with increased risk for death in any BMI category, according to study investigators.

A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.

The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.

Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.

Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.

Patients with IBD are often at an increased risk of developing NAFLD.

New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.

Dr. Blount discusses the DDW 2022 poster of distinction on the investigational live biotherapeutic.

Post-treatment, data show molecular age remained significantly greater than chronological age at a median difference of 18.6 years.

The data presented at DDW show similar safety and efficacy for the 2 treatments.

Recurrence commonly occurred during the first 2 weeks regardless of treatment.

Both post-transplant PPI and histamine-2 receptor antagonist use were independently associated with reduced risk of 1-year mortality.

DASH diet was inversely associated with NAFLD risk, independent of BMI changes.

The treatment did not improve sustained virologic response but did increase the rate of treatment-related adverse events.

There remains a need for longer-term observational studies comparing the 2 treatments.

Multiple studies have found a decrease in CDI rates during the COVID-19 pandemic in comparison to previous years.

Esophageal cancer has a low survival rate largely due to advanced stage diagnosis.

Nearly two-thirds of patients had improved or resolved EIM after ustekinumab treatment.

A large proportion of IBS-C patients did not seek health care during the COVID-19 pandemic despite symptoms.

Arena Pharmaceuticals expects to move forward with later phase clinical trials testing etrasimod.

Patients with opioid-induced constipation had more frequent, painful constipation symptoms, compared to those with chronic idiopathic constipation.

Direct optical endoscopy are often underutilized in screenings for EAC.

Data show patients with IBD and pathogen produced a unique pathogen-specific microbiome.

Dr. Evan Dellon said up to 8 biopsies for high risk patients could be beneficial in diagnosing different diseases impacting the esophagus.

COVID-19 patients with liver injuries are at a higher risk of mortality or lengthier hospital stays.

Data show nearly 1 in 10 patients with IBS-D in study were identified with SID.

Data show adverse events occurred in 6.67% in the cohort of patients with IBD.